LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

Stock Information for Veritone Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veritone Inc.

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.